| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $617.0M | +13.1% |
| Cost of Revenue | $150.2M | +4.8% |
| Gross Profit | $466.8M | +16.1% |
| R&D Expense | $155.0M | +1.2% |
| SG&A Expense | $141.8M | +23.8% |
| Operating Income | -$60.9M | +43.6% |
| Pre-tax Income | -$91.2M | +15.7% |
| Income Tax | $1.1M | -67.2% |
| Net Income | -$92.3M |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $118.6M | -20.6% |
| Short-term Investments | $41.3M | +327.9% |
| Accounts Receivable | $195.1M | +13.7% |
| Current Assets | $435.5M | +5.1% |
| Total Assets | $621.0M | -1.0% |
| Current Liabilities | $354.8M | -4.4% |
| Long-term Debt | $250.4M | +21.2% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $6.9M | +106.2% |
| Capital Expenditures | $3.8M | -60.6% |
| Investing Cash Flow | -$35.4M | -223.8% |
| Financing Cash Flow | -$258K | -100.3% |
| Free Cash Flow | $3.1M | +102.6% |
| +17.2% |
| EPS (Basic) | -$1.26 | +17.1% |
| EPS (Diluted) | -$1.26 | +17.1% |
| Total Liabilities |
| $653.7M |
| +13.7% |
| Stockholders' Equity | -$32.6M | -162.4% |